Oxford, UK – 30th September 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will include an OGT workshop entitled “Adding value through analysis”, which will explain how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders.
OGT’s targeted sequencing service is designed to provide meaningful results rather than insurmountable data sets. These are presented via an easy-to-use, interactive analysis report that makes it easy to sort, filter and prioritise the extensively annotated results. High-quality data is obtained using OGT’s internationally-recognised probe design and independently-accredited quality control procedures. OGT’s CEO Dr Mike Evans commented: “OGT is all about producing highly accurate, clear-cut results, and our new sequencing options can be easily combined with other aspects of our Genefficiency™ genomic services offering. In this way, microarray and sequencing data can be fully integrated to provide a highly validated and accurate genomic research solution”. For more details or to register for the workshop, please visit www.ogt.co.uk/go/register.
In addition to hosting this informative workshop, OGT will also be offering individual software demonstrations of its interactive sequencing report, which provides effortless access to biologically meaningful results. To register for a demonstration, contact OGT at firstname.lastname@example.org.
To find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.